Green machismo gets pumped up as Solazyme lands U.S. Navy biofuel deal

Algal synthetic biology startup Solazyme has been having a good summer. In addition to adding investors in its Series C (bringing the total of the round to $57 million), the company just landed an $8.5 million, high-visibility deal to develop and deliver 20,000 gallons of "Soladiesel" for the U.S. N...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Danimer Scientific throws Hail Mary to appease investors, acquiring Novomer for $152 million in cash

News Commentary | August 06, 2021

After going public via SPAC in December, Danimer Scientific has been under increased scrutiny, including a class‑action lawsuit for allegations that it overstated production figures, pricing, and financial projections for its core polyhydroxyalkanoate (PHA) technology – and looking for ways to re‑... Not part of subscription

Will Ginkgo-backed Arcaea "regenerate" the beauty industry with its $78 million Series A?

News Commentary | October 28, 2021

Arcaea is looking to answer what is possible for beauty by leveraging biotech to grow novel ingredients and create supply chains that don't rely on petrochemicals or scarce resources. So far, the company seems to have the means and partnerships to achieve its goals. It has a strong lineup of ... Not part of subscription

Israeli investment into digital health expected to rise significantly in 2022

News Commentary | February 08, 2022

A study conducted by Israel Advanced Technology Industries shows that 60% of Israeli venture capital (VC) investors expect to put more money into digital health in 2022. This projection follows a trend found in many of the broader areas of digital health since 2020. Segments like digital pain ... Not part of subscription